Tedizolid IV — Competitive Intelligence Brief

Tedizolid IV (Tedizolid IV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious Disease.

marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Tedizolid IV (Tedizolid IV) — University of Southern California. Tedizolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tedizolid IV TARGET	Tedizolid IV	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Linezolid Injectable Product	Linezolid Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Tedizolid PO	Tedizolid PO	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Topical Clindamycin	Topical Clindamycin	University of Toronto	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
mass treatment with oral azithromycin	mass treatment with oral azithromycin	University of California, San Francisco	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Linezolid (LZD)	Linezolid (LZD)	Wuhan Pulmonary Hospital	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
PRISTINAMYCIN XRP7263	PRISTINAMYCIN XRP7263	Sanofi	marketed	Macrolide antibiotic / Streptogramin	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

1. Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
2. University of Southern California · 2 drugs in this class
3. Arpida AG · 2 drugs in this class
4. Pfizer · 1 drug in this class
5. Shenzhen Third People's Hospital · 1 drug in this class
6. Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
7. Wuhan Pulmonary Hospital · 1 drug in this class
8. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class